BioCardia Inc. (NASDAQ:BCDA) shares fell 10.19% to $0.97 in after-hours trading Monday.

BioCardia is a biotechnology company developing cell therapies for cardiovascular diseases.

Nasdaq Compliance

BioCardia said Nasdaq notified the company that it had regained compliance with the $1 minimum bid price requirement after its closing bid price remained at $1 or greater for at least 10 consecutive business days.

The company had previously received a Nasdaq notice in August after its stock remained below the $1 minimum bid price requirement for 30 consecutive business days.

BioCardia said the notification has no effect on trading of its common stock, which continues to trade on the Nasdaq Capital Market under the ticker BCDA. The company also cautioned that there can be no assurance it will maintain compliance with the requirement in the future.

Trading Metrics, Technical Analysis

BioCardia has a market capitalization of approximately $16.35 million.

Over the past 12 months, BioCardia shares have fallen 2.7%.

The stock has traded between a 52-week high of $1.80 and a 52-week low of $0.75.

Benzinga’s Edge Stock Rankings show a positive price trend across the short- and medium-term time frames, while the long-term trend is negative.

Price Action: In the regular session, BioCardia shares fell 7.69% to close at $1.08.

Photo Courtesy: ZCOOL HelloRF on Shutterstock.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.